首页> 外文期刊>Vascular pharmacology >The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats.
【24h】

The influence of sulindac on diabetic cardiomyopathy: a non-invasive evaluation by Doppler echocardiography in streptozotocin-induced diabetic rats.

机译:舒林酸对糖尿病性心肌病的影响:多普勒超声心动图对链脲佐菌素诱发的糖尿病大鼠的非侵入性评估。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The aim of the present study was to investigate the cardioprotective activity of sulindac as an aldose reductase inhibitor in the development of cardiomyopathy by non-invasive techniques; M-mode and Doppler echocardiography. Diabetes was induced by streptozotocin (45 mg/kg, iv) in the Sprague-Dawley rats. Echocardiography, biochemical and histological studies were carried out in normal control, diabetic untreated, diabetic vehicle (sodium carboxy methyl cellulose, 1%, po) and sulindac (6 mg/kg and 20 mg/kg, po) treated animals at varying time intervals. In the diabetic untreated and vehicle treated rats at 12 weeks after induction of diabetes, there was a significant decrease in the E-wave, an increase in the A-wave and corresponding decrease in the E/A ratio was observed. Significant decrease in the Eat was found after 12 weeks (P < 0.05). Whereas systolic function variables; ejection fraction and fractional shortening were significantly decreased (P < 0.05) after 12 weeks compared to their baseline data. In the sulindac treated animals, there were no significant alterations in the systolic and diastolic parameters were found throughout the study period. Myocardial fructose levels were significantly increased in the diabetic untreated animals compared to normal control rats (P < 0.05), whereas these were significantly decreased in the sulindac (6 mg/kg and 20 mg/kg) treated animals (301.11+/-37.98, 214.11+/-25.31, vs. 914.88+/-56.01 nmol/g) compared to diabetic vehicle treated group (P < 0.05). Extensive focal ischemic myocyte degeneration was observed in the diabetic untreated and vehicle treated rats, whereas in the sulindac (6 mg/kg) treated rats, minimal necrosis was found, with no evidence of necrosis in sulindac (20 mg/kg) group. Our results show for the first time that sulindac has a cardioprotective activity as this agent prevented the development of left ventricular dysfunction in STZ-induced diabetic rats in the 12-week chronic study.
机译:本研究的目的是通过无创技术研究舒林酸作为醛糖还原酶抑制剂在心肌病发展中的心脏保护作用。 M型和多普勒超声心动图。链脲佐菌素(45 mg / kg,静脉注射)在Sprague-Dawley大鼠中诱发糖尿病。超声心动图,生化和组织学研究在不同时间间隔在正常对照组,未治疗的糖尿病,糖尿病媒介物(羧甲基纤维素钠,1%,口服)和舒林酸(6 mg / kg和20 mg / kg,口服)中进行过。在糖尿病诱导后第12周,未治疗和用媒介物治疗的糖尿病大鼠中,E波明显降低,A波增加,并且E / A比相应降低。 12周后发现进食量显着下降(P <0.05)。而收缩功能变量;与基线数据相比,射血分数和缩短分数缩短了12周后(P <0.05)。在舒林酸治疗的动物中,整个研究期间未发现收缩压和舒张压参数的显着变化。与正常对照组相比,未治疗的糖尿病动物的心肌果糖水平显着升高(P <0.05),而在舒林酸(6 mg / kg和20 mg / kg)治疗的动物中,心肌果糖水平显着降低(301.11 +/- 37.98,与糖尿病媒介物治疗组相比为214.11 +/- 25.31 vs.914.88 +/- 56.01 nmol / g)(P <0.05)。在未治疗和媒介物治疗的糖尿病大鼠中观察到广泛的局灶性缺血性心肌细胞变性,而在舒林酸(6 mg / kg)治疗的大鼠中,发现的坏死最小,而舒林酸(20 mg / kg)组没有坏死的迹象。我们的结果首次显示,舒林酸具有心脏保护活性,因为在12周的慢性研究中,舒林酸可预防STZ诱导的糖尿病大鼠左心室功能障碍的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号